PPAR-gamma: A noval therapeutic target for asthma

ottingham University0 个研究点目标入组 100 人开始时间: 2008年7月16日最近更新: 2019年2月28日

适应症

试验速览

暂无简介。

•Patients aged between 18-75 (Male or Female) with a clinical diagnosis of asthma. With a forecd expiratory volume (FEV) in 1 second 50-90% predicted and an increase in FEV1 >12% following inhaled salbutamol 400µg or peak expiratory flow (PEF) variability >12% during run-in.
•Allowed medication:0-800µg inhaled beclomethasone diproprionate or equivalent and as required short acting beta agonist.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria include current smokers or an ex-smoker with >10 pack years smoking history. Treatment with leukatriene antagonists, liver or cardiovascular disease, oral steroid treatment or exacerbation within 6 weeks. Females who are pregnant, lactating or not using adequate contraception. Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepactic impairment, diabetic ketoacidosis), oral or insulin treatment for diabetes, treatment with gemfibrozil or rifampicin.

发起方

ottingham University